Stock Analysis
- Germany
- /
- Healthcare Services
- /
- XTRA:ILM1
Medios Third Quarter 2023 Earnings: EPS: €0.30 (vs €0.25 in 3Q 2022)
Medios (ETR:ILM1) Third Quarter 2023 Results
Key Financial Results
- Revenue: €490.4m (up 17% from 3Q 2022).
- Net income: €7.10m (up 21% from 3Q 2022).
- Profit margin: 1.4% (in line with 3Q 2022).
- EPS: €0.30 (up from €0.25 in 3Q 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Medios Earnings Insights
Looking ahead, revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 1.6% decline forecast for the Healthcare industry in Germany.
Performance of the German Healthcare industry.
The company's shares are up 9.2% from a week ago.
Risk Analysis
It's still necessary to consider the ever-present spectre of investment risk. We've identified 1 warning sign with Medios, and understanding this should be part of your investment process.
Valuation is complex, but we're helping make it simple.
Find out whether Medios is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About XTRA:ILM1
Medios
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany.
Flawless balance sheet and undervalued.